Floatz logo

Exendin 9-39

Dumping Syndrome

Cambridge University Hospitals NHS Foundation TrustN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Dumping Syndrome cohort.

Asset / SponsorPhaseRating
Cabergoline
RECORDATI GROUP
Phase 4BB
Empagliflozin
Insel Gruppe AG, University Hospital Bern
Phase 4BB
Pasireotide
RECORDATI GROUP
Phase 4BB
Rifaximin
Cambridge University Hospitals NHS Foundation Trust
N/AD
Octreotide Pamoate
St. James's Hospital, Ireland
D

View all 9 →

Same molecule, other indications

Exendin 9-39 is also rated in:

obesity disorderDormant
B
Indicative ·
60 / 100
View asset →
Type 2 DiabetesDormant
D
Indicative ·
30 / 100
View asset →
morbid obesityDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →